We are live on ! Find out more
TCRT icon

Alaunos Therapeutics
TCRT

148 hedge funds and large institutions have $65.9M invested in Alaunos Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 41 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,587% more call options, than puts

Call options by funds: $5.45M | Put options by funds: $203K

0.13% less ownership

Funds ownership: 0.44% → 0.31% (-0.13%)

10% less funds holding

Funds holding: 165 → 148 (-17)

24% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 41

48% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 33

58% less capital invested

Capital invested by funds: $156M → $65.9M (-$89.9M)

Holders
148
Holders Change
-17
Holders Change %
-10.3%
% of All Funds
2.33%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
17
Increased
31
Reduced
41
Closed
33
Calls
$5.45M
Puts
$203K
Net Calls
+$5.25M
Net Calls Change
-$20.8M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$3.48M
2
N
Nuveen
North Carolina
+$649K
3
DCM
Discovery Capital Management
Connecticut
+$570K
4
Renaissance Technologies
Renaissance Technologies
New York
+$387K
5
GCP
GSA Capital Partners
United Kingdom
+$199K

Top Sellers

Rank Fund Capital Flow
1
MP
MSD Partners
New York
-$25.9M
2
State Street
State Street
Massachusetts
-$6.93M
3
Millennium Management
Millennium Management
New York
-$1.15M
4
Rafferty Asset Management
Rafferty Asset Management
New York
-$889K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$824K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
126
Aquatic Capital Management
Illinois
$5K +$3.08K +24 +96%
PHK
127
Point72 Hong Kong
Hong Kong
$5K +$6.93K +54 New
CAPTRUST Financial Advisors
128
CAPTRUST Financial Advisors
North Carolina
$4K – – –
NFSG
129
Newbridge Financial Services Group
Florida
$4K – – –
LWA
130
Lenox Wealth Advisors
New York
$3K – – –
COCM
131
Charter Oak Capital Management
New Hampshire
$2K – – –
KFI
132
Key Financial Inc
Pennsylvania
$2K – – –
S
133
SignatureFD
Georgia
$2K +$128 +1 +4%
Federated Hermes
134
Federated Hermes
Pennsylvania
$2K +$2.57K +20 New
APA
135
American Portfolios Advisors
New York
$1.37K – – –
EPM
136
Equitec Proprietary Markets
Illinois
$1K – – –
PA
137
PSI Advisors
Florida
$1K – – –
Fidelity Investments
138
Fidelity Investments
Massachusetts
$1K +$642 +5 New
PP
139
PFS Partners
New Jersey
$653 – – –
Macquarie Group
140
Macquarie Group
Australia
$18 – – –
Rafferty Asset Management
141
Rafferty Asset Management
New York
– -$889K -5,440 Closed
Wellington Management Group
142
Wellington Management Group
Massachusetts
– -$824K -5,041 Closed
APM
143
Avidity Partners Management
Texas
– -$643K -3,933 Closed
Qube Research & Technologies (QRT)
144
Qube Research & Technologies (QRT)
United Kingdom
– -$414K -2,532 Closed
Squarepoint
145
Squarepoint
New York
– -$144K -879 Closed
Marshall Wace
146
Marshall Wace
United Kingdom
– -$142K -871 Closed
AGM
147
Alpine Global Management
New York
– -$126K -771 Closed
MC
148
Manteio Capital
New Jersey
– -$114K -699 Closed
SPC
149
Sigma Planning Corp
Michigan
– -$80K -487 Closed
SWM
150
Sugarloaf Wealth Management
Georgia
– -$70K -427 Closed
3 4 5
6
7

TCRT Hedge Fund Activity: Q1 2022 in Review

148 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2022, worth a combined $65.9M — down 58% from $156M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of TCRT and 17 opened new positions — a net loss of 16 holders — while 41 trimmed existing stakes and 31 added.

The largest buyer was Goldman Sachs, adding an estimated $3.48M. The largest seller was MSD Partners, cutting an estimated $25.9M.

  • 148 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2022, down from 165 in Q4 2021.
  • Funds reported $65.9M of Alaunos Therapeutics stock for Q1 2022, down 58% quarter-over-quarter.
  • 17 funds opened new Alaunos Therapeutics positions in Q1 2022 and 33 closed out, a net change of -16 holders.
  • The largest Alaunos Therapeutics buyer in Q1 2022 was Goldman Sachs, an estimated $3.48M added.
  • The largest Alaunos Therapeutics seller in Q1 2022 was MSD Partners, an estimated $25.9M sold.

Based on aggregated 13F filings for Q1 2022.